Publication:
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation

dc.contributor.authorHurtado-Guerrero, Isaac
dc.contributor.authorHernáez, Bruno
dc.contributor.authorPinto-Medel, María Jesús
dc.contributor.authorCalonge, Esther
dc.contributor.authorRodriguez-Bada, José L
dc.contributor.authorUrbaneja, Patricia
dc.contributor.authorAlonso, Ana
dc.contributor.authorMena-Vázquez, Natalia
dc.contributor.authorAliaga, Pablo
dc.contributor.authorIssazadeh-Navikas, Shohreh
dc.contributor.authorPavia, José
dc.contributor.authorLeyva, Laura
dc.contributor.authorAlcamí, José
dc.contributor.authorAlcamí, Antonio
dc.contributor.authorFernández, Óscar
dc.contributor.authorOliver-Martos, Begoña
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderRegional Government of Andalusia (España)
dc.contributor.funderRed Temática de Investigación Cooperativa: Red Española de Esclerosis Múltiple (REEM) (España)
dc.date.accessioned2020-04-08T12:24:22Z
dc.date.available2020-04-08T12:24:22Z
dc.date.issued2020-03-31
dc.description.abstractSoluble receptors of cytokines are able to modify cytokine activities and therefore the immune system, and some have intrinsic biological activities without mediation from their cytokines. The soluble interferon beta (IFN-ß) receptor is generated through alternative splicing of IFNAR2 and has both agonist and antagonist properties for IFN-ß, but its role is unknown. We previously demonstrated that a recombinant human soluble IFN-ß receptor showed intrinsic therapeutic efficacy in a mouse model of multiple sclerosis. Here we evaluate the potential biological activities of recombinant sIFNAR2 without the mediation of IFN-ß in human cells. Recombinant sIFNAR2 down-regulated the production of IL-17 and IFN-ɣ and reduced the cell proliferation rate. Moreover, it showed a strong antiviral activity, fully protecting the cell monolayer after being infected by the virus. Specific inhibitors completely abrogated the antiviral activity of IFN-ß, but not that of the recombinant sIFNAR2, and there was no activation of the JAK-STAT signaling pathway. Consequently, r-sIFNAR2 exerts immunomodulatory, antiproliferative and antiviral activities without IFN-ß mediation, and could be a promising treatment against viral infections and immune-mediated diseases.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was funded by grants from the Instituto de Salud Carlos III and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” research project PI13/00927 and Technological Development Project in health DTS/1800045 to B. Oliver-Martos. Also, this work was partially supported by Instituto de Salud Carlos III and co-funded by European Regional Development Fund (ERDF) “A way to build Europe” (projects RD12/0017/0015 and RD16CIII/0002/0001). EMBO Short-TermFellowships (7902) and Estancias formativas de investigación, Junta de Andalucía (EF-0169-2018) to I. Hurtado. JL Rodriguez- Bada issupportedby grants from Red Temática de Investigación Cooperativa: Red Española de Esclerosis Multiple REEM (RD16/0015/0010). Thanks to the collaboration with the Lundbeck Foundation to S.I-N.es_ES
dc.format.number4es_ES
dc.format.page959es_ES
dc.format.volume9es_ES
dc.identifier.citationJ Clin Med. 2020 Mar 31;9(4). pii: E959.es_ES
dc.identifier.doi10.3390/jcm9040959es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.journalJournal of clinical medicinees_ES
dc.identifier.pubmedID32244308es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9486
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI13/00927es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/DTS/1800045es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ RD12/0017/0015es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0001es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/EF-0169-2018es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16/0015/0010es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm9040959es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectIFNARes_ES
dc.subjectImmunologyes_ES
dc.subjectInterferones_ES
dc.subjectSoluble receptorses_ES
dc.titleAntiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediationes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication5427ef71-65f2-46b8-a759-ce3ee260702b
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery5427ef71-65f2-46b8-a759-ce3ee260702b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublicationa16348d3-7483-4017-92f4-0f4f47980d57
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
AntiviralImmunomodulatoryAndAntiproliferative_2020.pdf
Size:
3.93 MB
Format:
Adobe Portable Document Format
Description: